<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610372</url>
  </required_header>
  <id_info>
    <org_study_id>H20-01207</org_study_id>
    <nct_id>NCT04610372</nct_id>
  </id_info>
  <brief_title>5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)</brief_title>
  <acronym>PROMPT</acronym>
  <official_title>Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy&#xD;
      (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam&#xD;
      radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate&#xD;
      cancer. Secondary aims include assessment of progression-free survival (PFS) and overall&#xD;
      survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will&#xD;
      maintain favorable toxicity profiles and quality of life while achieving comparable or better&#xD;
      efficacy, thereby providing a convenient and cost-effective alternative to moderately&#xD;
      hypofractionated EBRT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men newly diagnosed with low volume oligometastatic prostate cancer defined as fewer than 5&#xD;
      bone metastases and/or non regional lymph node involvement who agree to treatment of the&#xD;
      primary cancer with radiation will be randomized between standard moderately hypofractionated&#xD;
      external radiotherapy (5500 centiGray/20 fractions as per Stampede trial) and one of 3&#xD;
      alternatives: stereotactic body radiotherapy (SABR) to deliver 36 Gy/5 fractions, or low dose&#xD;
      rate Iodine 125 permanent seed implant or a single high dose rate temporary implant. The&#xD;
      trial will take place in 4 regional cancer centers of British Columbia Cancer Agency, with&#xD;
      each center choosing their preferred alternative to 5500/20. To achieve 4 equally sized&#xD;
      treatment arms, each randomization is weighted 3:1 for 42 patients in each arm and 168 total&#xD;
      accrual. The primary endpoint is urinary quality of life as assessed by the International&#xD;
      Prostate Symptom Score (IPSS) . As the typical acute symptoms from each of these radiation&#xD;
      modalities has a unique time course, assessments are done at 6 different points during the&#xD;
      first 2 years. Secondary endpoints are global quality of life as assessed by Expanded&#xD;
      Prostate Cancer Index (EPIC) urinary, bowel and sexual scores, progression free survival,&#xD;
      overall survival and cost effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There is one standard arm (5500/20) and 3 alternative arms. The alternative arms are center (or investigator) specific. Thus, each randomization is 2-way, but with a 3:1 weighting so that the 4 treatment arms have equal numbers of patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary symptoms</measure>
    <time_frame>Baseline to 2 years</time_frame>
    <description>International Prostate Symptom score (0/35), higher worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expanded Prostate Cancer Index (EPIC) urinary domain</measure>
    <time_frame>Baseline to 2 years</time_frame>
    <description>Urinary Quality of life, 0/100 higher score better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPIC bowel domain</measure>
    <time_frame>Baseline to 2 years</time_frame>
    <description>Bowel quality of life, 0/100, higher score better. Series of validated questions concerning urgency, frequency, consistency, leakage, presence of blood and pain with bowel movements and then rates how big a problem each symptom was (0-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPIC sexual domain</measure>
    <time_frame>Baseline to 2 years</time_frame>
    <description>Sexual quality of life, 0/100, higher score better. Series of validated questions concerning frequency and quality of erections, presence of morning erections, ability to engage in sexual activity or intercourse, rates ability and then rates importance of each issue to the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure (time to increase in prostate specific antigen (ng/ml) to 50% &gt; nadir</measure>
    <time_frame>Baseline to 3 years</time_frame>
    <description>Progression free survival measured as time to Prostate Specific Antigen (PSA) rise by 50% &gt; nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastatic failure</measure>
    <time_frame>Baseline to 3 years</time_frame>
    <description>Progression free survival measured as time to new or progressive bone metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodal progression</measure>
    <time_frame>Baseline to 3 years</time_frame>
    <description>Progression free survival measured as new or progressive adenopathy on imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival regardless of cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause specific survival</measure>
    <time_frame>Within 3 years of treatment</time_frame>
    <description>Death from prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis of primary treatment costs and secondary treatment costs at time of progression</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Oligometastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose rate brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Permanent seed implant brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic body radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated external beam radiotherapy</intervention_name>
    <description>5500 cGy/20 fractions delivered 5 days per week over 4 weeks</description>
    <arm_group_label>standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High dose rate brachytherapy</intervention_name>
    <description>A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance</description>
    <arm_group_label>High dose rate brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Permanent seed implant</intervention_name>
    <description>Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance</description>
    <arm_group_label>Permanent seed implant brachytherapy</arm_group_label>
    <other_name>Low dose rate brachytherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiotherapy</intervention_name>
    <description>External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.</description>
    <arm_group_label>Stereotactic body radiotherapy</arm_group_label>
    <other_name>SABR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  European Cooperative Oncology Group performance status 0 to 2&#xD;
&#xD;
          -  Medically fit for all protocol treatment and follow-up&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Newly diagnosed any Tumor stage, any Nodal stage but with oligo metastases&#xD;
&#xD;
          -  No prior therapy for prostate cancer apart from androgen deprivation&#xD;
&#xD;
          -  Luteinizing Hormone Releasing Hormone (LHRH) agonists or antagonists must have started&#xD;
             within 24 weeks of randomization&#xD;
&#xD;
          -  If used, anti-androgens must have started within 26 weeks of randomization&#xD;
&#xD;
          -  Able to complete the necessary investigations prior to and within 12 weeks of starting&#xD;
             Androgen Deprivation Therapy (ADT) or of randomization (History and physical&#xD;
             examination, PSA, Transrectal ultrasound-guided biopsy, CT or MRI abdomen and pelvis,&#xD;
             Bone scan)&#xD;
&#xD;
          -  Planned for long-term androgen deprivation therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High metastatic burden defined as 5 or more bone metastases or visceral metastases&#xD;
&#xD;
          -  Abnormal liver function&#xD;
&#xD;
          -  Contraindications to EBRT such as active inflammatory bowel disease or previous pelvic&#xD;
             radiation&#xD;
&#xD;
          -  Medically unfit for anesthesia&#xD;
&#xD;
          -  International Prostate Symptom Score (IPSS) greater than 20&#xD;
&#xD;
          -  Restrictive flow pattern with peak flow rate less than10 mL per second or post-void&#xD;
             residual greater than 25 per cent of voided volume (when uroflowmetry available)&#xD;
&#xD;
          -  Prostate volume greater than 60cc after maximal cytoreduction&#xD;
&#xD;
          -  Pubic arch interference&#xD;
&#xD;
          -  Transurethral resection of prostate (TURP) within 12 weeks of brachytherapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juanita Crook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BCCancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juanita Crook, MD</last_name>
    <phone>250 712 3958</phone>
    <email>jcrook@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francois Bachand, MD</last_name>
    <phone>250 712 3966</phone>
    <email>fbachand@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>British Columbia Cancer Agency Center for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Juanita Crook, MD</last_name>
      <phone>250 712 3958</phone>
      <email>jcrook@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Francois Bachand, MD</last_name>
      <phone>250 712 3900</phone>
      <email>fbachand@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Deidre Batchelar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Araujo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Petrik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Hilts, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Halperin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moore Jocelyn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koulis Theodora, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Halperin Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fraser Valley Cancer Center</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Winkle Kwan, MD</last_name>
      <email>wkwan@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver Cancer Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mira Keyes, MD</last_name>
      <phone>604-266-6444</phone>
      <email>mkeyes@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver Island Cancer Center</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Abe Alexander, MD</last_name>
      <email>AAlexander3@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Saibish Elantholi Parmeswaran, MD</last_name>
      <email>Saibishkumar.ElantholiParmeswaran@bccancer.bc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>British Columbia Cancer Agency</investigator_affiliation>
    <investigator_full_name>Juanita Crook</investigator_full_name>
    <investigator_title>Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>prostate adenocarcinoma</keyword>
  <keyword>oligometastases</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>hypofractionation</keyword>
  <keyword>brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

